Nov 27 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental drug to treat severe major depressive disorder had failed to meet the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.41 USD | +2.30% | +0.86% | -18.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.78% | 2.82B | |
+16.13% | 122B | |
+19.65% | 113B | |
+18.57% | 26.49B | |
-23.84% | 19.4B | |
-18.61% | 16.24B | |
-19.28% | 15.4B | |
-45.95% | 15.15B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals' depression drug fails to meet main goal in study